<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051570</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000663630</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2009-087</secondary_id>
    <secondary_id>NOVARTIS-WSU-2009-087</secondary_id>
    <nct_id>NCT01051570</nct_id>
  </id_info>
  <brief_title>Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel</brief_title>
  <official_title>Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together
      with everolimus and prednisone may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving carboplatin together with everolimus
      and prednisone works in treating patients with metastatic prostate cancer that progressed
      after docetaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the time to progression (TTP) achieved with carboplatin and everolimus in
           patients with castrate resistant metastatic prostate cancer that progressed after
           docetaxel-based chemotherapy.

      Secondary

        -  To evaluate the safety of this regimen.

        -  To assess the PSA response rate in patients treated with this regimen.

        -  To evaluate the overall survival (OS) outcome in these patients.

        -  To investigate the association of TTP and PSA response rate with correlative markers,
           such as phospho mTOR, pAKT, and p70S6.

        -  To evaluate the pharmacokinetics of this regimen.

        -  To explore the association of TTP, OS, and circulating tumor tumor cell count.

      OUTLINE: Patients receive carboplatin IV over 30-60 minutes on day 1, oral prednisone twice
      daily on days on days 1-21, and oral everolimus once daily on days 2-21 of course 1 and on
      days 1-21 of subsequent courses. Courses repeat every 21 days in the absence of disease
      progression or unacceptable toxicity.

      Blood and tumor tissue samples are collected periodically for pharmacodynamic,
      pharmacokinetic, and biomarker analysis.

      After completion of study treatment, patients are followed up every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to 63 days while on treatment, then up 90 days thereafter. From date of registration to date of progressive disease.</time_frame>
    <description>Progression defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Measured by NCI CTCAE v3.0 Criteria</measure>
    <time_frame>Day 1 of each cycle (every 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response Rate</measure>
    <time_frame>Day 1 of each cycle (every 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of TTP and PSA Response Rate With Correlative Markers (Phospho mTOR, pAKT, and p70S6)</measure>
    <time_frame>Archival tissue will be collected if available. Optional biopsies pre-treatment and 24 hours after first everolimus and carboplatin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>After treatment, participants will be contacted every 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin, RAD 001 &amp; Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle
RAD 001: 5 mg Orally daily, starting from Day 2 continuously
Prednisone 5 mg Orally twice daily, continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC = 5 by Calvert's formula, day 1 of each 21 day cycle</description>
    <arm_group_label>Carboplatin, RAD 001 &amp; Prednisone</arm_group_label>
    <other_name>Paraplatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD 001</intervention_name>
    <description>5 mg orally starting on Day 2 then continuous</description>
    <arm_group_label>Carboplatin, RAD 001 &amp; Prednisone</arm_group_label>
    <other_name>Afinitor®</other_name>
    <other_name>Zortress</other_name>
    <other_name>Everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>5 mg orally twice a day starting on Day 1 then continuous</description>
    <arm_group_label>Carboplatin, RAD 001 &amp; Prednisone</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Liquid Pred</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Orasone</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicot</other_name>
    <other_name>Sterapred</other_name>
    <other_name>Sterapred DS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Samples will be collected from archival tissue.</description>
    <arm_group_label>Carboplatin, RAD 001 &amp; Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</description>
    <arm_group_label>Carboplatin, RAD 001 &amp; Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic adenocarcinoma of the prostate

          -  Objective disease progression or rising PSA despite androgen deprivation therapy and
             antiandrogen withdrawal (when applicable)

          -  Progressed after ≥ 1 prior docetaxel-based chemotherapy regimen for metastatic disease

               -  Patients with measurable disease* must have either rising PSA, increase in size
                  of the lesion(s), or both

                    -  Patients with rising PSA as the only evidence of disease progression must
                       demonstrate a rising trend with 2 successive elevations ≥ 1 week apart

               -  Patients with no measurable disease must have a PSA ≥ 5 ng/mL or new areas of
                  bony metastases on bone scan NOTE: *There is no minimum PSA requirement for
                  patients with measurable disease

          -  Documented to be castrate with a testosterone level of ≤ 0.5 ng/mL

               -  Leuteinizing hormone-releasing hormone agonist therapy must be continued, if
                  required to maintain castrate levels of testosterone

          -  No uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  ANC ≥ 1,500/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

          -  Platelet count ≥ 100,000/mm^3

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Calculated creatinine clearance ≥ 50 mL/min OR serum creatinine ≤ 2 mg/dL

          -  AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase
             ≤ 4 times ULN if AST and/or ALT normal (for patients without documented bone
             metastases or for patients with liver metastases)

          -  AST and/or ALT &lt; 2.5 times ULN, without regard to alkaline phosphatase levels (for
             patients with documented bone metastases)

          -  Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5
             times ULN (in the case that one or both of these thresholds are exceeded, the patient
             is eligible only after initiation of appropriate lipid-lowering medication)

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study treatment

          -  Willing and able to comply with this study

          -  Able to ingest oral medication

          -  No other malignancies except non-melanoma skin cancer or any other adequately treated
             cancer in complete remission for ≥ 2 years

          -  No significant traumatic injury within the past 4 weeks

          -  No active (acute or chronic) or uncontrolled severe infections

          -  No severe and/or uncontrolled medical conditions or other conditions that could affect
             study participation, including the following:

               -  NYHA class III-IV symptomatic congestive heart failure

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction within the past 6 months, serious uncontrolled cardiac arrhythmia, or
                  any other clinically significant cardiac disease

               -  Severely impaired lung function as defined by spirometry and DLCO that is 50% of
                  the normal predicted value and/or oxygen saturation that is ≤ 88% at rest on room
                  air

               -  Uncontrolled diabetes as defined by fasting serum glucose &gt; 1.5 times ULN

               -  Liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent
                  hepatitis

               -  Known history of HIV seropositivity, hepatitis B or C

               -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
                  alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled
                  nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

               -  Active, bleeding diathesis

          -  No known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus)
             or to their excipients

          -  No history of noncompliance to medical regimens

          -  No uncontrolled diabetes mellitus

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 1 prior docetaxel based regimen for metastatic disease

               -  Docetaxel based combination therapy or docetaxel alone considered as 1 regimen

          -  No more than 2 prior chemotherapy regimens for metastatic disease

          -  No prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)

          -  At least 6 weeks since prior bicalutamide or nilutamide

          -  At least 4 weeks since prior flutamide

          -  More than 4 weeks since prior and no other concurrent investigational drugs

          -  More than 4 weeks since prior and no other concurrent anticancer therapies (including
             chemotherapy, radiotherapy, or antibody-based therapy)

          -  More than 4 weeks since prior and no concurrent major surgery (defined as requiring
             general anesthesia) and recovered

          -  More than 1 week since prior and no concurrent immunization with attenuated live
             vaccines

          -  No concurrent chronic, systemic treatment with corticosteroids or other
             immunosuppressive agents

               -  Topical or inhaled corticosteroids are allowed

          -  No concurrent prophylactic growth factors

          -  Concurrent bisphosphonate therapy allowed
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulka N. Vaishampayan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northshore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <results_first_submitted>August 9, 2014</results_first_submitted>
  <results_first_submitted_qc>August 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2014</results_first_posted>
  <last_update_submitted>February 11, 2018</last_update_submitted>
  <last_update_submitted_qc>February 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ulka Vaishampayan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hormone-resistant prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboplatin, RAD 001 &amp; Prednisone</title>
          <description>Carboplatin: AUC=4 by Calvert’s formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle
RAD 001: 5 mg Orally daily, starting from Day 2 continuously
Prednisone 5 mg Orally twice daily, continuously
carboplatin: AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
RAD 001: 5 mg orally starting on Day 2 then continuous
prednisone: 5 mg orally twice a day starting on Day 1 then continuous
laboratory biomarker analysis: Samples will be collected from archival tissue.
pharmacological study: Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboplatin, RAD 001 &amp; Prednisone</title>
          <description>Carboplatin: AUC=4 by Calvert’s formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle
RAD 001: 5 mg Orally daily, starting from Day 2 continuously
Prednisone 5 mg Orally twice daily, continuously
carboplatin: AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
RAD 001: 5 mg orally starting on Day 2 then continuous
prednisone: 5 mg orally twice a day starting on Day 1 then continuous
laboratory biomarker analysis: Samples will be collected from archival tissue.
pharmacological study: Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="54" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP)</title>
        <description>Progression defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Up to 63 days while on treatment, then up 90 days thereafter. From date of registration to date of progressive disease.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, RAD 001 &amp; Prednisone</title>
            <description>Carboplatin: AUC=4 by Calvert’s formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle
RAD 001: 5 mg Orally daily, starting from Day 2 continuously
Prednisone 5 mg Orally twice daily, continuously
carboplatin: AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
RAD 001: 5 mg orally starting on Day 2 then continuous
prednisone: 5 mg orally twice a day starting on Day 1 then continuous
laboratory biomarker analysis: Samples will be collected from archival tissue.
pharmacological study: Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>Progression defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.8" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Measured by NCI CTCAE v3.0 Criteria</title>
        <time_frame>Day 1 of each cycle (every 21 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Response Rate</title>
        <time_frame>Day 1 of each cycle (every 21 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of TTP and PSA Response Rate With Correlative Markers (Phospho mTOR, pAKT, and p70S6)</title>
        <time_frame>Archival tissue will be collected if available. Optional biopsies pre-treatment and 24 hours after first everolimus and carboplatin dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics</title>
        <time_frame>Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>After treatment, participants will be contacted every 3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carboplatin, RAD 001 &amp; Prednisone</title>
          <description>Carboplatin: AUC=4 by Calvert’s formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle
RAD 001: 5 mg Orally daily, starting from Day 2 continuously
Prednisone 5 mg Orally twice daily, continuously
carboplatin: AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
RAD 001: 5 mg orally starting on Day 2 then continuous
prednisone: 5 mg orally twice a day starting on Day 1 then continuous
laboratory biomarker analysis: Samples will be collected from archival tissue.
pharmacological study: Samples will be collected Cycle 1, day 1, 2 &amp; 8 and Cycle 2, Day 1 &amp; 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Inf_wo_neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis_PE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Inf_wo_neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory_Neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size; Correlates were conducted in &lt;50% of the patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ulka N. Vaishampayan, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8718</phone>
      <email>vaishamu@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

